Idiopathic recurrent pericarditis
MONDO:0016662A rare autoinflammatory syndrome defined as recurrence of pericardial inflammation of unknown origin following the first episode of acute pericarditis and a symptom-free interval of 4-6 weeks or longer. Recurrent attacks of chest pain may be the sole presentation or the chest pain may be accompanied by pericardial friction rub, electrocardiographic or echocardiographic changes, pericardial effusion and increased C-reactive protein. Cardiac tamponade is a rare, life-threatening complication.
Also known as: idiopathic relapsing pericarditis
18 clinical trials for this condition and its sub-types, 8 tagged with Idiopathic recurrent pericarditis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for heart lining pain: can CardiolRx keep flare-ups away?
Disease control Recruiting nowThis study tests whether the drug CardiolRx can prevent another episode of pericarditis (inflammation around the heart) in people who have had repeated attacks. About 110 adults who have been stable on an IL-1 blocker for at least a year will stop that medication and receive eith…
Phase 3 • Sponsor: Cardiol Therapeutics Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for heart inflammation sufferers: experimental drug VTX2735 enters Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental drug called VTX2735 in 50 adults with recurrent pericarditis, a condition where the heart's lining becomes inflamed and painful. The goal is to see if the drug is safe and can reduce pain and inflammation. Participants receive different doses over…
Phase 2 • Sponsor: Zomagen Biosciences Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New shot aims to stop repeat heart sac inflammation
Disease control Recruiting nowThis study tests an injected drug called KPL-387 in 165 people with recurrent pericarditis, a condition where the sac around the heart becomes inflamed again and again. The goal is to see if KPL-387 can reduce flare-ups and pain better than a placebo. Participants must have sympt…
Phase 2/3 • Sponsor: Kiniksa Pharmaceuticals International, plc • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New shot aims to keep pericarditis Flare-Ups at bay
Disease control Recruiting nowThis study tests a new drug called KPL-387 in 80 people with well-controlled recurrent pericarditis (inflammation around the heart). The goal is to see if patients can safely switch from their current treatments to KPL-387 alone and still prevent flare-ups. The trial will measure…
Phase 2 • Sponsor: Kiniksa Pharmaceuticals International, plc • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC